Author

Jinkun Zhang

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

Jinkun Zhang  et al.

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION
EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Jinkun Zhang  et al.

Item 1 - 2 / 2
1